Lotfi S, Nasser H, Noyori O, Hiyoshi M, Takeuchi H, Koyanagi Y
Retrovirology. 2020; 17(1):20.
PMID: 32650782
PMC: 7350586.
DOI: 10.1186/s12977-020-00528-y.
Doi N, Koma T, Adachi A, Nomaguchi M
Front Microbiol. 2019; 10:2758.
PMID: 31849897
PMC: 6893887.
DOI: 10.3389/fmicb.2019.02758.
Murmann A, Bartom E, Schipma M, Vilker J, Chen S, Peter M
iScience. 2019; 23(2):100737.
PMID: 31838022
PMC: 7033618.
DOI: 10.1016/j.isci.2019.11.031.
Nomaguchi M, Doi N, Yoshida T, Koma T, Adachi S, Ode H
Front Microbiol. 2018; 8:2542.
PMID: 29326677
PMC: 5741601.
DOI: 10.3389/fmicb.2017.02542.
Li G, De Clercq E
Microbiol Mol Biol Rev. 2016; 80(3):679-731.
PMID: 27357278
PMC: 4981665.
DOI: 10.1128/MMBR.00065-15.
HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor.
Bashir T, Patgaonkar M, Kumar S, Pasi A, Reddy K
PLoS One. 2015; 10(4):e0124839.
PMID: 25915507
PMC: 4411102.
DOI: 10.1371/journal.pone.0124839.
Targeting RNA-protein interactions within the human immunodeficiency virus type 1 lifecycle.
Bell N, LHernault A, Murat P, Richards J, Lever A, Balasubramanian S
Biochemistry. 2013; 52(51):9269-74.
PMID: 24358934
PMC: 3928988.
DOI: 10.1021/bi401270d.
A noncanonical mu-1A-binding motif in the N terminus of HIV-1 Nef determines its ability to downregulate major histocompatibility complex class I in T lymphocytes.
Iijima S, Lee Y, Ode H, Arold S, Kimura N, Yokoyama M
J Virol. 2012; 86(7):3944-51.
PMID: 22301137
PMC: 3302484.
DOI: 10.1128/JVI.06257-11.
The identification of a small molecule compound that reduces HIV-1 Nef-mediated viral infectivity enhancement.
Chutiwitoonchai N, Hiyoshi M, Mwimanzi P, Ueno T, Adachi A, Ode H
PLoS One. 2011; 6(11):e27696.
PMID: 22110726
PMC: 3217016.
DOI: 10.1371/journal.pone.0027696.
Interactions between Nef and AIP1 proliferate multivesicular bodies and facilitate egress of HIV-1.
Costa L, Chen N, Lopes A, Aguiar R, Tanuri A, Plemenitas A
Retrovirology. 2006; 3:33.
PMID: 16764724
PMC: 1526754.
DOI: 10.1186/1742-4690-3-33.
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.
Kao S, Khan M, Miyagi E, Plishka R, Buckler-White A, Strebel K
J Virol. 2003; 77(21):11398-407.
PMID: 14557625
PMC: 229358.
DOI: 10.1128/jvi.77.21.11398-11407.2003.
Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions.
Gaddis N, Chertova E, Sheehy A, Henderson L, Malim M
J Virol. 2003; 77(10):5810-20.
PMID: 12719574
PMC: 154025.
DOI: 10.1128/jvi.77.10.5810-5820.2003.
Amino acid residues 88 and 89 in the central hydrophilic region of human immunodeficiency virus type 1 Vif are critical for viral infectivity by enhancing the steady-state expression of Vif.
Fujita M, Sakurai A, Yoshida A, Miyaura M, Koyama A, Sakai K
J Virol. 2002; 77(2):1626-32.
PMID: 12502880
PMC: 140823.
DOI: 10.1128/jvi.77.2.1626-1632.2003.
Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection.
Kao S, Akari H, Khan M, Dettenhofer M, Yu X, Strebel K
J Virol. 2002; 77(2):1131-40.
PMID: 12502829
PMC: 140813.
DOI: 10.1128/jvi.77.2.1131-1140.2003.
Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function.
Khan M, Akari H, Kao S, Aberham C, Davis D, Buckler-White A
J Virol. 2002; 76(18):9112-23.
PMID: 12186895
PMC: 136454.
DOI: 10.1128/jvi.76.18.9112-9123.2002.
Characterization of producer cell-dependent restriction of murine leukemia virus replication.
Serhan F, Jourdan N, Saleun S, Moullier P, Duisit G
J Virol. 2002; 76(13):6609-17.
PMID: 12050374
PMC: 136263.
DOI: 10.1128/jvi.76.13.6609-6617.2002.
Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.
Khan M, Aberham C, Kao S, Akari H, Gorelick R, Bour S
J Virol. 2001; 75(16):7252-65.
PMID: 11461998
PMC: 114961.
DOI: 10.1128/JVI.75.16.7252-7265.2001.
Characterization of a late entry event in the replication cycle of human immunodeficiency virus type 2.
McKnight A , Griffiths D, Dittmar M, Clapham P, Thomas E
J Virol. 2001; 75(15):6914-22.
PMID: 11435571
PMC: 114419.
DOI: 10.1128/JVI.75.15.6914-6922.2001.
Cell-dependent requirement of human immunodeficiency virus type 1 gp41 cytoplasmic tail for Env incorporation into virions.
Akari H, Fukumori T, Adachi A
J Virol. 2000; 74(10):4891-3.
PMID: 10775630
PMC: 112014.
DOI: 10.1128/jvi.74.10.4891-4893.2000.
Nef-induced major histocompatibility complex class I down-regulation is functionally dissociated from its virion incorporation, enhancement of viral infectivity, and CD4 down-regulation.
Akari H, Arold S, Fukumori T, Okazaki T, Strebel K, Adachi A
J Virol. 2000; 74(6):2907-12.
PMID: 10684310
PMC: 111784.
DOI: 10.1128/jvi.74.6.2907-2912.2000.